Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
63,624,754
-
Shares change
-
+1,349,292
-
Total reported value, excl. options
-
$952,552,077
-
Value change
-
+$19,485,332
-
Put/Call ratio
-
57%
-
Number of buys
-
80
-
Number of sells
-
-42
-
Price
-
$14.97
Significant Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q2 2025
151 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value as of Q2 2025.
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63,624,754 shares
of 81,149,970 outstanding shares and own 78% of the company stock.
Largest 10 shareholders include FMR LLC (9,053,034 shares), Fairmount Funds Management LLC (4,018,101 shares), BlackRock, Inc. (4,007,296 shares), RTW INVESTMENTS, LP (3,621,996 shares), TANG CAPITAL MANAGEMENT LLC (3,200,000 shares), VANGUARD GROUP INC (3,066,586 shares), VR ADVISER, LLC (2,685,448 shares), BRAIDWELL LP (2,578,404 shares), Capital International Investors (2,392,541 shares), and Driehaus Capital Management LLC (2,085,590 shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.